Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel,…
Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for…
Read More...
Read More...
